Company Overview

NKGen Biotech, Inc. is a clinical-stage biotechnology company focused on the development of natural killer (NK) cell–based immunotherapies. The company operates within the biotechnology and cell therapy industries, with a primary emphasis on leveraging a patient’s own immune system to target cancer and neurodegenerative diseases. Its core development program centers on autologous NK cell therapy intended to enhance immune response without genetic modification.

The company’s principal product candidate is SNK01, an autologous, non-genetically modified NK cell therapy being evaluated in multiple clinical indications, including Alzheimer’s disease, Parkinson’s disease, and certain oncology settings. NKGen positions itself as differentiated from CAR-NK and CAR-T developers by focusing on scalable, non-engineered NK cell expansion, which may reduce manufacturing complexity and safety risks. NKGen Biotech was founded in 2017 and became a publicly traded company in 2023 through a merger transaction, after which its common stock began trading on Nasdaq under the ticker NKGN.

Business Operations

NKGen’s operations are organized around a single reportable business focused on the research, development, and potential commercialization of NK cell immunotherapies. Revenue generation is currently non-commercial, as the company remains in the clinical development stage and does not yet market approved products. Its operational activities primarily include clinical trials, process development for cell expansion, regulatory engagement, and intellectual property management.

The company controls proprietary NK cell expansion and activation processes used in the manufacture of SNK01, conducted through internally managed and contracted facilities. NKGen conducts clinical research in collaboration with academic medical centers and hospitals, particularly in the United States and Asia, but does not disclose material revenue-generating partnerships. Its primary operating subsidiary is NKMax America, Inc., which supports development and administrative activities.

Strategic Position & Investments

Strategically, NKGen is focused on advancing SNK01 through mid-stage clinical trials while exploring additional indications where NK cell dysfunction is implicated. Growth initiatives emphasize expanding clinical data in neurodegenerative diseases, an area with limited disease-modifying treatment options, as well as selectively evaluating oncology applications. The company has stated that it intends to pursue regulatory pathways that could allow for accelerated development if clinical efficacy is demonstrated.

NKGen has not disclosed significant acquisitions but has invested in internal manufacturing know-how and clinical infrastructure. Its strategic positioning highlights emerging interest in innate immune cell therapy, particularly non-genetically modified approaches, as a complementary or alternative modality to adaptive immune cell therapies. Data inconclusive based on available public sources regarding near-term licensing or large-scale pharmaceutical partnerships.

Geographic Footprint

NKGen Biotech is headquartered in the United States, with executive management and corporate operations based in California. The company maintains an operational and clinical presence in the United States and Asia, reflecting its origins and ongoing clinical collaborations.

Clinical trials and research activities have been conducted in the United States, South Korea, and other parts of Asia, giving the company a trans-Pacific operational footprint. While NKGen does not currently generate international commercial revenue, its development strategy indicates an intent to pursue global regulatory approvals and future market access across North America and Asia-Pacific regions.

Leadership & Governance

NKGen was founded by physician-scientists with experience in immunology and clinical medicine, shaping a leadership philosophy centered on translational science and patient-driven therapy development. The company is governed by a board and executive team with backgrounds in biotechnology, medicine, and public company operations. Its strategic vision emphasizes disciplined clinical execution, safety-focused development, and scalable cell therapy manufacturing.

Key executives include:

• Paul Y. Song, MD – Chairman and Chief Executive Officer
• Steve Go, CPA – Chief Financial Officer
• Jason D. Lee, PhD – Chief Scientific Officer
• Young H. Kim, MD, PhD – Chief Medical Officer

The leadership team collectively guides NKGen’s clinical strategy, regulatory engagement, and capital allocation as the company advances its pipeline toward later-stage development.